• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Arcutis Biotherapeutics Inc.

    5/15/25 5:41:18 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARQT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    Arcutis Biotherapeutics, Inc.

    (Name of Issuer)


    Common

    (Title of Class of Securities)


    03969K108

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    03969K108


    1Names of Reporting Persons

    PRUDENTIAL FINANCIAL INC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NEW JERSEY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    198,527.00
    6Shared Voting Power

    11,755,543.00
    7Sole Dispositive Power

    198,527.00
    8Shared Dispositive Power

    11,755,543.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    11,954,070.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.1 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Arcutis Biotherapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE, CALIFORNIA, 91361.
    Item 2. 
    (a)Name of person filing:

    Prudential Financial, Inc.
    (b)Address or principal business office or, if none, residence:

    751 Broad Street Newark, New Jersey 07102-3777
    (c)Citizenship:

    New Jersey
    (d)Title of class of securities:

    Common
    (e)CUSIP No.:

    03969K108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    11,954,070
    (b)Percent of class:

    10.1  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    198,527

     (ii) Shared power to vote or to direct the vote:

    11,755,543

     (iii) Sole power to dispose or to direct the disposition of:

    198,527

     (iv) Shared power to dispose or to direct the disposition of:

    11,755,543

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Our clients may have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities which are the subject of this filing.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Prudential Financial, Inc. is a Parent Holding Company and the indirect parent of the following subsidiaries, who are the beneficial owners of the number and percentage of securities which are the subject of this filing as set forth next to their names: Subsidiaries Number of shares Percentage Jennison Associates LLC IA 11,360,875 9.6 PGIM, Inc. IA 585,000 0.5 PGIM Quantitative Solutions LLC IA 8,195 0.0
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    PRUDENTIAL FINANCIAL INC
     
    Signature:RICHARD BAKER
    Name/Title:SECOND VICE PRESIDENT
    Date:05/15/2025
    Get the next $ARQT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARQT

    DatePrice TargetRatingAnalyst
    12/30/2024$19.00Buy
    H.C. Wainwright
    8/28/2024$15.00Buy
    Jefferies
    1/3/2024$4.00 → $8.00Neutral → Buy
    Mizuho
    10/26/2023$57.00 → $4.00Buy → Neutral
    Mizuho
    10/13/2023$32.00 → $6.00Buy → Neutral
    Goldman
    9/7/2022$46.00Buy
    Needham
    3/17/2022$45.00Buy
    Goldman
    3/2/2022$35.00 → $37.00Overweight
    Morgan Stanley
    More analyst ratings

    $ARQT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice

      Arcutis convened the Genital Psoriasis Wellness Consortium, a multidisciplinary group of clinicians who are experts in their fieldsPublication includes 14 consensus statements aimed at improving diagnosis, treatment, outcomes, and shared decision-makingGenital involvement occurs in approximately two-thirds of the nine million individuals with plaque psoriasis WESTLAKE VILLAGE, Calif., May 15, 2025 (GLOBE NEWSWIRE) --  Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the publication of 14 consensus statements from the Genital Psoriasis Wellness Consortium on the impa

      5/15/25 9:29:01 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology

      Once-daily, investigational ZORYVE foam 0.3%, rapidly improved psoriasis of the scalp and body, including itch, when used as a monotherapy66.4% of individuals treated with ZORYVE foam achieved Scalp-Investigator Global Assessment (S-IGA) Success at Week 845.5% of individuals treated with ZORYVE foam achieved Body-Investigator Global Assessment (B-IGA) Success at Week 8Efficacy and safety results were consistent with Phase 2 results of ZORYVE foam 0.3% in adults and adolescents 12 years of age and olderSupplemental New Drug Application (sNDA) for investigational ZORYVE foam 0.3% for psoriasis is under review with U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (P

      5/7/25 11:18:26 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update

      Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible resets and insurance changes, and excluding the non-recurring reduction in reserves for product return of $4.1 million reported in Q4 2024Continued demand growth for ZORYVE of 10%, solidifying its position as most prescribed branded non-steroidal topical treatment across three major inflammatory skin conditionsAll three largest national Pharmacy Benefit Managers (PBMs) covering entire ZORYVE portfolio and Medicaid coverage continues to expandOn April 3, 2025, the patent litigation against Padagis was

      5/6/25 4:00:00 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARQT
    Leadership Updates

    Live Leadership Updates

    See more
    • Arcutis Appoints L. Todd Edwards as Chief Commercial Officer

      Industry veteran with deep commercial experience in dermatology and immunologyAyisha Jeter appointed Senior Vice President, Marketing and Market Access WESTLAKE VILLAGE, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the appointment of Todd Edwards as Chief Commercial Officer (CCO), effective immediately. Mr. Edwards brings to Arcutis over 25 years of sales, market access, marketing, and general management experience from leading companies in dermatology and immunology, including Incyte, UCB, and AbbVie. "We are t

      9/27/23 8:00:00 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcutis Announces Leadership Transition

      Senior Vice President and Chief Commercial Officer (CCO) Ken Lock Stepping DownAyisha Jeter Appointed Interim CCO WESTLAKE VILLAGE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced a leadership change. Ken Lock, who has served as Senior Vice President and Chief Commercial Officer (CCO) since October 2019, is stepping down to attend to personal matters effective June 2, 2023. During this transition period, Arcutis' Vice President of Market Access, Ayisha Jeter, has been appointed interim CCO. Mr. Lock's contributions t

      5/24/23 5:00:03 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcutis Appoints Mas Matsuda as General Counsel and Corporate Secretary

      WESTLAKE VILLAGE, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the appointment of Mas Matsuda, Esq. as General Counsel and Corporate Secretary. Mr. Matsuda joins Arcutis from Halozyme Therapeutics Inc. and succeeds Keith Klein, Esq. who announced his retirement after a successful 30-year industry career. In this role, Mr. Matsuda will oversee all legal and compliance matters for the Company. "On behalf of our entire team, we'd like to thank Keith for his considerable contributions to our efforts in establishing Arcutis as a le

      12/16/21 8:00:00 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARQT
    Financials

    Live finance-specific insights

    See more
    • Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update

      Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible resets and insurance changes, and excluding the non-recurring reduction in reserves for product return of $4.1 million reported in Q4 2024Continued demand growth for ZORYVE of 10%, solidifying its position as most prescribed branded non-steroidal topical treatment across three major inflammatory skin conditionsAll three largest national Pharmacy Benefit Managers (PBMs) covering entire ZORYVE portfolio and Medicaid coverage continues to expandOn April 3, 2025, the patent litigation against Padagis was

      5/6/25 4:00:00 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

      WESTLAKE VILLAGE, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report first quarter 2025 financial results and provide a business update on Tuesday, May 6, 2025 after the U.S. financial markets close. The Company will also host a conference call and webcast the same day at 4:30 p.m. ET. A live webcast of the call and the presentation materials will be available on the "Events" section of The Company's website. An archived replay of the webcast will be available on the Arcutis investor website following th

      4/17/25 8:00:00 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      WESTLAKE VILLAGE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Q4 2024 net product revenue for ZORYVE® (roflumilast) was $69.4 million, a 413% increase compared to Q4 of 2023 and a 55% increase compared to Q3 of 2024; driven by strong portfolio demand growth and including a non-recurring adjustment of $4.1 million due to a reduction in reserves for product returnsFull Year 2024 net product revenue for ZORYVE was $166.5 million, an increase of 471% over the prior year, setting the stage for sustained growth and strong financial position in 2025ZORYVE is now the most prescribed branded non-steroidal topical treatment across three major inflammatory skin conditions combined in the United StatesS

      2/25/25 4:00:00 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARQT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Heron Patrick J bought $119,352 worth of shares (8,674 units at $13.76) (SEC Form 4)

      4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

      5/15/25 4:18:54 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Heron Patrick J bought $85,691 worth of shares (6,300 units at $13.60) (SEC Form 4)

      4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

      5/13/25 4:11:38 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Edwards Larry Todd bought $7,767 worth of shares (1,093 units at $7.11), increasing direct ownership by 0.80% to 137,728 units (SEC Form 4)

      4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

      12/3/24 4:17:09 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARQT
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Arcutis Biotherapeutics Inc.

      SCHEDULE 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

      5/15/25 5:41:18 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Arcutis Biotherapeutics Inc.

      SCHEDULE 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

      5/8/25 5:59:00 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Arcutis Biotherapeutics Inc.

      144 - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

      5/8/25 2:54:55 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARQT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Arcutis Biotherapeutics Inc.

      SC 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

      11/14/24 7:50:59 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arcutis Biotherapeutics Inc.

      SC 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

      11/13/24 4:30:25 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arcutis Biotherapeutics Inc.

      SC 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

      11/6/24 4:00:53 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARQT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Heron Patrick J bought $119,352 worth of shares (8,674 units at $13.76) (SEC Form 4)

      4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

      5/15/25 4:18:54 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Heron Patrick J bought $85,691 worth of shares (6,300 units at $13.60) (SEC Form 4)

      4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

      5/13/25 4:11:38 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Burnett Patrick sold $52,623 worth of shares (3,871 units at $13.59), decreasing direct ownership by 3% to 115,468 units (SEC Form 4)

      4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

      5/9/25 7:45:47 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARQT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Arcutis Biotherapeutics with a new price target

      H.C. Wainwright initiated coverage of Arcutis Biotherapeutics with a rating of Buy and set a new price target of $19.00

      12/30/24 7:23:09 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Arcutis Biotherapeutics with a new price target

      Jefferies initiated coverage of Arcutis Biotherapeutics with a rating of Buy and set a new price target of $15.00

      8/28/24 7:20:44 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcutis Biotherapeutics upgraded by Mizuho with a new price target

      Mizuho upgraded Arcutis Biotherapeutics from Neutral to Buy and set a new price target of $8.00 from $4.00 previously

      1/3/24 7:32:19 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARQT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

      Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form

      12/19/23 3:40:08 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

      Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

      12/15/23 5:01:31 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care